Cargando…
The role of Angiogenesis and remodeling (AR) associated signature for predicting prognosis and clinical outcome of immunotherapy in pan-cancer
BACKGROUND: Angiogenesis and remodeling (AR) is necessary for the growth and metastasis of cancers. Although AR related genes involved in this process are reported, the correlation between AR and clinical outcome, immune cell infiltration, and immunotherapy is still unknown in diverse cancers. This...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719961/ https://www.ncbi.nlm.nih.gov/pubmed/36479101 http://dx.doi.org/10.3389/fimmu.2022.1033967 |
_version_ | 1784843444276953088 |
---|---|
author | Sun, Xiaojiao Zhang, Zhuo Wang, Zhiqi Xie, Ran Yi, Chuxiao Liu, Huiyu Chi, Xiaowei Li, Tiancheng Liu, Haitao Han, Yi Pang, Xiaocong Cui, Yimin Liu, Zhenming |
author_facet | Sun, Xiaojiao Zhang, Zhuo Wang, Zhiqi Xie, Ran Yi, Chuxiao Liu, Huiyu Chi, Xiaowei Li, Tiancheng Liu, Haitao Han, Yi Pang, Xiaocong Cui, Yimin Liu, Zhenming |
author_sort | Sun, Xiaojiao |
collection | PubMed |
description | BACKGROUND: Angiogenesis and remodeling (AR) is necessary for the growth and metastasis of cancers. Although AR related genes involved in this process are reported, the correlation between AR and clinical outcome, immune cell infiltration, and immunotherapy is still unknown in diverse cancers. This study aimed to investigate the role of AR in the tumor immune microenvironment (TIME) in pan-cancer, and explore its values in prognostic prediction and therapeutic responses. METHODS: Firstly, AR genes (including angiogenesis genes and blood vessel remodeling genes) are collected from MsigDB database. The differential expression, and prognostic value of AR genes were studied in 33 tumor types based on TCGA and GTEx data. The AR score of each sample was calculated using the “ssGSEA” function of R package “GSVA” in pan-cancer. The correlation of the AR score with TIME index, such as the amount of stromal and immune components and the immune cell infiltration, was evaluated via integrating multiple computational methods. And we also utilized IMvigor210 and GSE78220 data to explore the prediction value of the AR score on the immunotherapy response. RESULTS: Significant differences in AR gene expression between tumors and adjacent normal tissues were found in most cancer types. The AR score varied depending on the types of tumors, and high score was related to worse survival in various tumors, such as pancreatic and stomach adenocarcinoma and so on. Moreover, the AR score was further explored to be positively correlated with proportions and pathways of immune and stromal in TIME. And the AR score was positively correlated with immunosuppressive cells, including TAMs and iTregs, while negatively with CD8+ T cells. Further analysis revealed that patients with high AR had worse therapy efficacy and survival status in bladder cancer and melanomas. CONCLUSIONS: Our systematic analysis revealed that AR is closely associated TIME, and prognosis, and clinical characteristics in multiple cancers. Targeting AR genes may activate immune microenvironment and increase the efficacy of immunotherapy. |
format | Online Article Text |
id | pubmed-9719961 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97199612022-12-06 The role of Angiogenesis and remodeling (AR) associated signature for predicting prognosis and clinical outcome of immunotherapy in pan-cancer Sun, Xiaojiao Zhang, Zhuo Wang, Zhiqi Xie, Ran Yi, Chuxiao Liu, Huiyu Chi, Xiaowei Li, Tiancheng Liu, Haitao Han, Yi Pang, Xiaocong Cui, Yimin Liu, Zhenming Front Immunol Immunology BACKGROUND: Angiogenesis and remodeling (AR) is necessary for the growth and metastasis of cancers. Although AR related genes involved in this process are reported, the correlation between AR and clinical outcome, immune cell infiltration, and immunotherapy is still unknown in diverse cancers. This study aimed to investigate the role of AR in the tumor immune microenvironment (TIME) in pan-cancer, and explore its values in prognostic prediction and therapeutic responses. METHODS: Firstly, AR genes (including angiogenesis genes and blood vessel remodeling genes) are collected from MsigDB database. The differential expression, and prognostic value of AR genes were studied in 33 tumor types based on TCGA and GTEx data. The AR score of each sample was calculated using the “ssGSEA” function of R package “GSVA” in pan-cancer. The correlation of the AR score with TIME index, such as the amount of stromal and immune components and the immune cell infiltration, was evaluated via integrating multiple computational methods. And we also utilized IMvigor210 and GSE78220 data to explore the prediction value of the AR score on the immunotherapy response. RESULTS: Significant differences in AR gene expression between tumors and adjacent normal tissues were found in most cancer types. The AR score varied depending on the types of tumors, and high score was related to worse survival in various tumors, such as pancreatic and stomach adenocarcinoma and so on. Moreover, the AR score was further explored to be positively correlated with proportions and pathways of immune and stromal in TIME. And the AR score was positively correlated with immunosuppressive cells, including TAMs and iTregs, while negatively with CD8+ T cells. Further analysis revealed that patients with high AR had worse therapy efficacy and survival status in bladder cancer and melanomas. CONCLUSIONS: Our systematic analysis revealed that AR is closely associated TIME, and prognosis, and clinical characteristics in multiple cancers. Targeting AR genes may activate immune microenvironment and increase the efficacy of immunotherapy. Frontiers Media S.A. 2022-11-21 /pmc/articles/PMC9719961/ /pubmed/36479101 http://dx.doi.org/10.3389/fimmu.2022.1033967 Text en Copyright © 2022 Sun, Zhang, Wang, Xie, Yi, Liu, Chi, Li, Liu, Han, Pang, Cui and Liu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Sun, Xiaojiao Zhang, Zhuo Wang, Zhiqi Xie, Ran Yi, Chuxiao Liu, Huiyu Chi, Xiaowei Li, Tiancheng Liu, Haitao Han, Yi Pang, Xiaocong Cui, Yimin Liu, Zhenming The role of Angiogenesis and remodeling (AR) associated signature for predicting prognosis and clinical outcome of immunotherapy in pan-cancer |
title | The role of Angiogenesis and remodeling (AR) associated signature for predicting prognosis and clinical outcome of immunotherapy in pan-cancer |
title_full | The role of Angiogenesis and remodeling (AR) associated signature for predicting prognosis and clinical outcome of immunotherapy in pan-cancer |
title_fullStr | The role of Angiogenesis and remodeling (AR) associated signature for predicting prognosis and clinical outcome of immunotherapy in pan-cancer |
title_full_unstemmed | The role of Angiogenesis and remodeling (AR) associated signature for predicting prognosis and clinical outcome of immunotherapy in pan-cancer |
title_short | The role of Angiogenesis and remodeling (AR) associated signature for predicting prognosis and clinical outcome of immunotherapy in pan-cancer |
title_sort | role of angiogenesis and remodeling (ar) associated signature for predicting prognosis and clinical outcome of immunotherapy in pan-cancer |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719961/ https://www.ncbi.nlm.nih.gov/pubmed/36479101 http://dx.doi.org/10.3389/fimmu.2022.1033967 |
work_keys_str_mv | AT sunxiaojiao theroleofangiogenesisandremodelingarassociatedsignatureforpredictingprognosisandclinicaloutcomeofimmunotherapyinpancancer AT zhangzhuo theroleofangiogenesisandremodelingarassociatedsignatureforpredictingprognosisandclinicaloutcomeofimmunotherapyinpancancer AT wangzhiqi theroleofangiogenesisandremodelingarassociatedsignatureforpredictingprognosisandclinicaloutcomeofimmunotherapyinpancancer AT xieran theroleofangiogenesisandremodelingarassociatedsignatureforpredictingprognosisandclinicaloutcomeofimmunotherapyinpancancer AT yichuxiao theroleofangiogenesisandremodelingarassociatedsignatureforpredictingprognosisandclinicaloutcomeofimmunotherapyinpancancer AT liuhuiyu theroleofangiogenesisandremodelingarassociatedsignatureforpredictingprognosisandclinicaloutcomeofimmunotherapyinpancancer AT chixiaowei theroleofangiogenesisandremodelingarassociatedsignatureforpredictingprognosisandclinicaloutcomeofimmunotherapyinpancancer AT litiancheng theroleofangiogenesisandremodelingarassociatedsignatureforpredictingprognosisandclinicaloutcomeofimmunotherapyinpancancer AT liuhaitao theroleofangiogenesisandremodelingarassociatedsignatureforpredictingprognosisandclinicaloutcomeofimmunotherapyinpancancer AT hanyi theroleofangiogenesisandremodelingarassociatedsignatureforpredictingprognosisandclinicaloutcomeofimmunotherapyinpancancer AT pangxiaocong theroleofangiogenesisandremodelingarassociatedsignatureforpredictingprognosisandclinicaloutcomeofimmunotherapyinpancancer AT cuiyimin theroleofangiogenesisandremodelingarassociatedsignatureforpredictingprognosisandclinicaloutcomeofimmunotherapyinpancancer AT liuzhenming theroleofangiogenesisandremodelingarassociatedsignatureforpredictingprognosisandclinicaloutcomeofimmunotherapyinpancancer AT sunxiaojiao roleofangiogenesisandremodelingarassociatedsignatureforpredictingprognosisandclinicaloutcomeofimmunotherapyinpancancer AT zhangzhuo roleofangiogenesisandremodelingarassociatedsignatureforpredictingprognosisandclinicaloutcomeofimmunotherapyinpancancer AT wangzhiqi roleofangiogenesisandremodelingarassociatedsignatureforpredictingprognosisandclinicaloutcomeofimmunotherapyinpancancer AT xieran roleofangiogenesisandremodelingarassociatedsignatureforpredictingprognosisandclinicaloutcomeofimmunotherapyinpancancer AT yichuxiao roleofangiogenesisandremodelingarassociatedsignatureforpredictingprognosisandclinicaloutcomeofimmunotherapyinpancancer AT liuhuiyu roleofangiogenesisandremodelingarassociatedsignatureforpredictingprognosisandclinicaloutcomeofimmunotherapyinpancancer AT chixiaowei roleofangiogenesisandremodelingarassociatedsignatureforpredictingprognosisandclinicaloutcomeofimmunotherapyinpancancer AT litiancheng roleofangiogenesisandremodelingarassociatedsignatureforpredictingprognosisandclinicaloutcomeofimmunotherapyinpancancer AT liuhaitao roleofangiogenesisandremodelingarassociatedsignatureforpredictingprognosisandclinicaloutcomeofimmunotherapyinpancancer AT hanyi roleofangiogenesisandremodelingarassociatedsignatureforpredictingprognosisandclinicaloutcomeofimmunotherapyinpancancer AT pangxiaocong roleofangiogenesisandremodelingarassociatedsignatureforpredictingprognosisandclinicaloutcomeofimmunotherapyinpancancer AT cuiyimin roleofangiogenesisandremodelingarassociatedsignatureforpredictingprognosisandclinicaloutcomeofimmunotherapyinpancancer AT liuzhenming roleofangiogenesisandremodelingarassociatedsignatureforpredictingprognosisandclinicaloutcomeofimmunotherapyinpancancer |